Modulation of ribosomal frameshifting frequency and its effect on the replication of rous sarcoma virus

Journal of Virology

Volumn 86, Issue 21, 2012, Pages 11581-11594

  Nikolić, Emily I C ^a   King, Louise M ^a   Vidakovic, Marijana ^a   Irigoyen, Nerea ^a   Brierley, Ian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; GAG PROTEIN; POL PROTEIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; FREQUENCY MODULATION; GENE SEQUENCE; GENETIC TRANSFECTION; GROUP SPECIFIC ANTIGEN GENE; HEPTANUCLEOTIDE SLIPPERY SEQUENCE; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RIBOSOMAL FRAMESHIFTING; RNA STRUCTURE; ROUS SARCOMA ONCOVIRUS; SIGNAL TRANSDUCTION; STRUCTURAL GENE; VIRUS GENE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIABILITY;

BASE SEQUENCE; FRAMESHIFTING, RIBOSOMAL; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; NUCLEIC ACID CONFORMATION; POINT MUTATION; RNA, VIRAL; ROUS SARCOMA VIRUS; VIRUS REPLICATION;

ALPHARETROVIRUS; RICE STRIPE VIRUS; RNA VIRUSES; ROUS SARCOMA VIRUS;

EID: 84869065502     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01846-12     Document Type: Article

References (51)

1. Aupeix-Scheidler K, et al. 2000. Inhibition of in vitro and ex vivo translation by a transplatin-modified oligo (2=-O-methylribonucleotide) directed against the HIV-1 gag-pol frameshift signal. Nucleic Acids Res.28:438-445.
2. Babé LM, Pichuantes S, Craik CS. 1991. Inhibition of HIV protease activity by heterodimer formation. Biochemistry 30:106 -111.
3. Bidou L, Rousset JP, Namy O. 2010. Translational errors: from yeast to new therapeutic targets. FEMS Yeast Res. 10:1070 -1082.
4. Bieth E, Darlix JL. 1992. Complete nucleotide sequence of a highly infectious avian leukosis virus. Nucleic Acids Res. 20:367.
5. Biswas P, Jiang X, Pacchia AL, Dougherty JP, Peltz SW. 2004. The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy.J. Virol. 78:2082-2087.
6. Brierley I, Digard P, Inglis SC. 1989. Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell 57:537-547
7. Brierley I, Gilbert RJC, Pennell S. 2010. Pseudoknot-dependent programmed -1 ribosomal frameshifting: structures, mechanisms and models,p 149-174. In Atkins JF, Gesteland RF (ed), Recoding: expansion of decoding rules enriches gene expression. Springer, New York, NY
8. Brierley I, Jenner AJ, Inglis SC. 1992. Mutational analysis of the "slippery-sequence" component of a coronavirus ribosomal frameshifting signal. J. Mol. Biol. 227:463-479.
9. Cherry E, et al. 1998. Characterization of human immunodeficiencyvirus type-1 (HIV-1) particles that express protease-reverse transcriptasefusion proteins. J. Mol. Biol. 284:43-56
10. Dinman JD, Wickner RB. 1992. Ribosomal frameshifting efficiency and Gag/Gag-Pol ratio are critical for yeast M1 double-stranded RNA virus propagation. J. Virol. 66:3669 -3676
11. Dinman JD, Kinzy TG. 1997. Translational misreading: mutations in translation elongation factor 1alpha differentially affect programmed ribosomal frameshifting and drug sensitivity. RNA 3:870-881.
12. Dinman JD, Ruiz-Echevarria MJ, Peltz SW. 1998. Translating old drugs into new treatments: ribosomal frameshifting as a target for antiviral agents. Trends Biotechnol. 16:190 -196
13. Dulude D, Berchiche YA, Gendron K, Brakier-Gingras L, Heveker N.2006. Decreasing the frameshift efficiency translates into an equivalent reduction of the r eplication of the human immunodeficiency virus type 1.Virology 345:127-136.
14. Dulude D, Théberge-Julien G, Brakier-Gingras L, Heveker N. 2008.Selection of peptides interfering with a ribosomal frameshift in the human immunodeficiency virus type 1. RNA 14:981-991
15. Enssle J, Jordan I, Mauer B, Rethwilm A. 1996. Foamy virus reverse transcriptase is expressed independently from the Gag protein. Proc. Natl.Acad. Sci. U.S.A. 93:4137- 4141.
16. Felsenstein KM, Goff SP. 1988. Expression of the Gag-Pol fusion protein of Moloney murine leukemia virus without Gag protein does not induce virion formation or proteolytic processing. J. Virol. 62:2179 -2182.
17. Fujimura T, Esteban R, Esteban LM, Wickner RB. 1990. Portable encapsidation signal of the L-A double-stranded RNA virus of S. cerevisiae.Cell 62:819-828.
18. Gareiss PC, Miller BL. 2009. Ribosomal frameshifting: an emerging drug target for HIV. Curr. Opin. Investig. Drugs 10:121-128.
19. Gheysen D, et al. 1989. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59:103-112.
20. Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF, Atkins JF. 1998. A dual-luciferase reporter system for studying recoding signals.RNA4:479-486.
21. Hill MK, Shehu-Xhilaga M, Crowe SM, Mak J. 2002. Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability.J. Virol. 76:11245-11253
22. Hughes SH, Greenhouse JJ, Petropoulos CJ, Sutrave P. 1987. Adaptorplasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J. Virol. 61:3004 -3012
23. Hughes SH, et al. 2008. The RCAS system. http://home.ncifcrf.gov/hivdrp/RCAS/index.html
24. Hung M, Patel P, Davis S, Green SR. 1998. Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication. J. Virol. 72:4819-4824
25. Jacks T, Varmus HE. 1985. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science 230:1237-1242.
26. Jacks T, Madhani HD, Masiarz FR, Varmus HE. 1988. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell55:447-458.
27. Jaskólski M, Miller M, Rao JK, Leis J, Wlodawer A. 1990. Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2Â resolution. Biochemistry 29:5889 -5898.
28. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B. 1993. Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193:661-671.
29. Katz RA, et al. 1982. Restriction endonuclease and nucleotide sequence analyses of molecularly cloned unintegrated avian tumor virus DNA:structure of large terminal repeats in circle junctions. J. Virol. 42:346 -351.
30. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
31. Leiherer A, Ludwig C, Wagner R. 2009. Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication. J. Virol. 283:7210 -7220.
32. Marcheschi RJ, Mouzakis KD, Butcher SE. 2009. Selection and characterization of small molecules that bind the HIV-1 frameshift site RNA.ACS Chem. Biol. 4:844-854.
33. Marczinke B, Fisher R, Vidaković M, Bloys AJ, Brierley I. 1998. Secondary structure and mutational analysis of the ribosomal frameshift signal of Rous sarcoma virus. J. Mol. Biol. 284:205-225.
34. McNaughton BR, Gareiss PC, Miller BL. 2007. Identification of a selective small-molecule ligand for HIV-1 frameshift-inducing stem-loopRNA from an 11,325 member resin bound dynamic combinatorial library. J.Am. Chem. Soc. 129:11306 -11307.
35. Miller M, Jaskólski M, Rao JK, Leis J, Wlodawer A. 1989. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 337:576-579.
36. Miyauchi K, et al. 2006. Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin. Antivir. Chem. Chemother. 17:167-174.
37. Neuman BW, et al. 2005. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79:9665-9676
38. Palde PB, Ofori LO, Gareiss PC, Lerea J, Miller BL. 2010. Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence. J. Med. Chem. 53:6018-6027
39. Park SJ, Kim YG, Park HJ. 2011. Identification of RNA pseudoknotbinding ligand that inhibits the -1 ribosomal frameshifting of SARScoronavirus by structure-based virtual screening. J. Am. Chem. Soc. 133:10094-10100
40. Plant EP, Rakauskaite R, Taylor DR, Dinman JD. 2010. Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins. J. Virol. 84:4330-4340
41. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27:493- 497
42. Schwartz DE, Tizard R, Gilbert W. 1983. Nucleotide sequence of Rous sarcoma virus. Cell 32:853- 869
43. Shehu-Xhilaga M, Crowe SM, Mak J. 2001. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1RNA dimerization and viral infectivity. J. Virol. 75:1834 -1841
44. Stewart L, Vogt VM. 1994. Proteolytic cleavage at the Gag-Pol junction in avian leukosis virus: differences in vitro and in vivo. Virology 204:45-59.
45. Telenti A, et al. 2002. Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J. Virol. 76:7868 -7873
46. Tibbles KW, Brierley I, Cavanagh D, Brown TD. 1995. A region of the coronavirus infectious bronchitis virus 1a polyprotein encoding the 3Clike protease domain is subject to rapid turnover when expressed in rabbit reticulocyte lysate. J. Gen. Virol. 76:3059 -3070.
47. Vickers TA, Ecker DJ. 1992. Enhancement of ribosomal frameshifting by oligonucleotides targeted to the HIV gag-pol region. Nucleic Acids Res.20:3945-3953
48. Voynow SL, Coffin JM. 1985. Truncated Gag-related proteins are produced by large deletion mutants of Rous sarcoma virus and form virus particles. J. Virol. 55 :79-85.
49. Weber IT. 1990. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases.J. Biol. Chem. 265:10492-10496.
50. Yoshinaka Y, Katoh I, Copeland TD, Oroszlan S. 1985. Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc. Natl. Acad. Sci. U.S.A. 82:1618 -1622
51. Yu CH, Noteborn MH, Olsthoorn RC. 2010. Stimulation of ribosomal frameshifting by antisense LNA. Nucleic Acids Res. 38:8277-8283.